Why Barclays Is Still Overweight McKesson After 30% Gain
10h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mckessonbarclays
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Barclays reaffirmed its Overweight rating on shares of pharmaceutical distributor McKesson Corporation on June 13th, 2026. This analyst endorsement arrives as the stock trades near an all-time high, having appreciated approximately 30% over the preceding twelve months. The firm’s stance underscores confidence in the healthcare distribution sector’s fundamental resilience amid persistent inflationary and interest rate pressures. Institutional flows into defensive healthcare names have accelerated in the second quarter of 2026, with McKesson capturing a significant portion.
The decision to maintain a bullish stance on a stock at its peak reflects a belief in continued fundamental momentum. The last comparable analyst action for McKesson was a similar Overweight reiteration by BofA Securities on April 2, 2026, which preceded a 7% price gain over the subsequent eight weeks. The current macro backdrop features the US 10-year Treasury yield at 4.15% and Federal Reserve policy firmly in focus. What triggered the reaffirmation now is the conclusion of the fiscal Q1 2027 earnings season for major distributors, which demonstrated sustained revenue growth exceeding 5% year-over-year despite broader economic deceleration fears. This performance has shifted the narrative from cyclical concern to structural durability.
McKesson's stock price closed at $745.60 on June 12th, 2026. The company's market capitalization stands at approximately $92.4 billion. Its forward price-to-earnings ratio of 20.3 sits at a 15% premium to its five-year average of 17.6. This valuation expansion has occurred alongside consistent earnings beats; the company has exceeded consensus EPS estimates in seven of the past eight quarters. A comparison of key metrics before and after its last major earnings report on May 1st, 2026, shows the stock rose from $712.50 to $738.20 within five trading days. Year-to-date, MCK is up 14.2%, which outpaces the 8.7% gain for the SPDR S&P Pharmaceuticals ETF (XPH) and the S&P 500's 7.9% return. Pharmaceutical distributor peer AmerisourceBergen trades at a forward P/E of 18.1, representing a 12% discount to McKesson.
| Metric | McKesson (MCK) | S&P 500 Healthcare Sector (XLV) |
|---|---|---|
| YTD Return | +14.2% | +6.1% |
| 1-Year Return | +30.1% | +11.4% |
| Forward P/E | 20.3 | 18.9 |
The sustained bullishness on McKesson signals institutional conviction in the distribution middleman segment of healthcare. Second-order effects likely benefit other major distributors like AmerisourceBergen (ABC) and Cardinal Health (CAH), as the entire sector’s valuation framework is re-rated upward. Companies providing logistics and automation technologies to these distributors, such as Omnicell (OMCL), may also see increased investor interest. A key limitation or counter-argument is that McKesson’s premium valuation leaves little room for error; any guidance miss or regulatory change affecting drug pricing could precipitate a sharp correction. Positioning data from the Options Clearing Corporation indicates elevated call option volume for MCK in the $750-$760 strike range for July expiry, suggesting traders are positioning for a continued breakout. Hedge fund net exposure to the healthcare distribution group increased by 22% in Q2 2026, per recent 13F filings.
The immediate catalyst is the upcoming US PCE Price Index report on June 27th, 2026, which will influence interest rate expectations and sector rotations. McKesson’s next quarterly earnings report is scheduled for July 31st, 2026, where gross margin trajectory will be a primary focus. Technical levels to monitor include near-term support at the 50-day moving average of $728.40 and resistance at the psychologically significant $750 level. A sustained break above $750 on high volume would confirm the bullish technical thesis. If the July earnings report shows margin compression, the stock could retest support near $710, aligning with its 100-day moving average. The broader performance of the healthcare sector will be tested by the next round of Medicare drug price negotiations, with updated guidance expected in September 2026.
An Overweight rating is an analyst's recommendation that a stock is expected to outperform the average return of its sector or a benchmark index over a specified period, typically 12-18 months. For McKesson shareholders, this Barclays reiteration suggests the firm believes the stock's recent strong performance has further room to run, based on fundamentals like revenue durability and operational execution. It often signals to institutional investors that the stock remains a core holding within the healthcare allocation.
McKesson's current forward P/E ratio of approximately 20.3 represents a significant expansion from its pre-pandemic average. In fiscal year 2019, the company traded at an average forward P/E of around 12.5. This near-doubling of the valuation multiple reflects a permanent re-rating by the market, which now assigns a higher premium to the stability of healthcare distribution cash flows and the sector's critical, non-discretionary role in the economy, factors that were underscored during the COVID-19 health crisis.
The primary risks include increased direct-to-pharmacy or direct-to-consumer distribution by drug manufacturers, which could disintermediate companies like McKesson. Regulatory efforts to lower US drug prices, such as the Inflation Reduction Act's Medicare negotiation provisions, could pressure margins across the pharmaceutical supply chain. shifts toward specialty and high-cost biologic drugs, which often have different distribution channels, require continuous and capital-intensive adaptation from traditional wholesale distributors.
Barclays believes McKesson's structural advantages justify its premium valuation and will drive further outperformance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.